Gadolinium-enhanced cardiac magnetic resonance imaging: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines

Gadolinium-enhanced cardiac magnetic resonance imaging: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines

Bibliographic Details
Main Authors:	Nacif Marcelo, Arai Andrew E, Lima Joao A, Bluemke David A
Format:	Article
Language:	English
Published:	BMC 2012-02-01
Series:	Journal of Cardiovascular Magnetic Resonance

Similar Items

Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines
by: Nacif Marcelo S, et al.
Published: (2012-02-01)

Accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis
by: Al-Mallah Mouaz H, et al.
Published: (2009-01-01)

Medical Economics: End the FDA (Food and Drug Administration)
by: John Romanach, et al.
Published: (2017-03-01)

Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance
by: Francisca Caetano, et al.
Published: (2014-05-01)

Cardiac resynchronization therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance
by: Smith Russell EA, et al.
Published: (2011-06-01)

Image quality of late gadolinium enhancement in cardiac magnetic resonance with different doses of contrast material in patients with chronic myocardial infarction
by: Caterina Beatrice Monti, et al.
Published: (2020-04-01)

Prognostic value of adenosine stress perfusion cardiac magnetic resonance with late gadolinium enhancement
by: Teo Karen S, et al.
Published: (2011-02-01)

Cardiac magnetic resonance left ventricular quantitative analysis post gadolinium: reliable and reproducible?
by: Shambrook James S, et al.
Published: (2011-02-01)

Late gadolinium enhancement patterns on cardiac magnetic resonance images in heart transplant patients
by: Chiariello Massimo, et al.
Published: (2010-01-01)

Neurotoxic manifestations of high-dose intrathecal gadolinium administration for CT myelogram
by: Pannaga Malalur, MD, et al.
Published: (2020-10-01)

Myocardial bridging in patients with hypertrophic cardiomyopathy is not associated with late gadolinium enhancement at cardiac magnetic resonance imaging
by: Hees Tilman A, et al.
Published: (2013-01-01)

Diagnostic questions in hypertrophic cardiomyopathy: What is the significance of late gadolinium enhancement on cardiac magnetic resonance?
by: Ana G. Almeida
Published: (2014-05-01)

Unique pattern of late gadolinium enhancement on cardiac magnetic resonance imaging in Duchenne muscular dystrophy
by: Madhusudan Ganigara, et al.
Published: (2016-01-01)

Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy
by: Christina Doesch, et al.
Published: (2017-07-01)

Value of late gadolinium enhancement by magnetic resonance in patients with cardiac sarcoidosis: characteristic findings and clinical utility
by: Kawana Masatoshi, et al.
Published: (2009-01-01)

Late gadolinium enhancement cardiovascular magnetic resonance for sudden cardiac death risk stratification in hypertrophic cardiomyopathy
by: Ismail Tevfik F, et al.
Published: (2013-01-01)

Screening prior to gadolinium based contrast agent administration: A UK survey of guideline implementation and adherence
by: Snaith, Beverly, et al.
Published: (2018)

Combined stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance provides robust prognostic data to cardiac events
by: Blankstein Ron, et al.
Published: (2010-01-01)

Resonance evaluation of Gadolinium isotopes
by: Leal Luiz, et al.
Published: (2020-01-01)

Myocardial Viability on Cardiac Magnetic Resonance
by: Ana Luiza Mansur Souto, et al.

Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials
by: Liu Songtao, et al.
Published: (2012-12-01)

Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
by: Amira Osman, et al.
Published: (2018-04-01)

Rationale for Use of an FDA-Cleared Delivery System for Administration of Inhaled Nitric Oxide in Patients Undergoing Magnetic Resonance Imaging
by: Salas M, et al.
Published: (2021-01-01)

Prognostic utility of late gadolinium enhancement cardiac magnetic resonance imaging in coronary artery disease: a meta-analysis
by: Chan Raymond H, et al.
Published: (2013-01-01)

Quantitative assessment of late gadolinium-enhancement in cardiac magnetic resonance predicts left ventricular remodeling in acute myocarditis
by: Villoteau Serge, et al.
Published: (2010-01-01)

Atypical Distribution of Late Gadolinium Enhancement of the Left Ventricle on Cardiac Magnetic Resonance in Classical Anderson-Fabry Disease
by: Shusuke Kasuya, et al.
Published: (2016-01-01)

Cardiac magnetic resonance imaging and gadolinium angiography for neonates and small infants: a 10-year single institutional experience
by: Rangamani Sheela, et al.
Published: (2012-02-01)

Combined stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance provides robust prognostic information to cardiac events
by: Jerosch-Herold Michael, et al.
Published: (2011-02-01)

Can late gadolinium enhancement on cardiovascular magnetic resonance describe cardiac involvement in patients with systemic sarcoidosis and/or suspect of cardiac involvement of sarcoidosis with cardiac symptoms?
by: Shuji Sakai, et al.
Published: (2011-02-01)

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
by: Lauren L. Spiegel, et al.
Published: (2020-05-01)

Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
by: Felix W. Frueh, et al.
Published: (2013-06-01)

Myocardial tissue characterisation using gadolinium cardiovascular magnetic resonance
by: Moon, James Charles Connor
Published: (2005)

Magnetic Resonance Imaging of synovitis without the use of intravenous gadolinium
by: Burnett, Carole
Published: (2015)

Repeat and single dose administration of gadodiamide to rats to investigate concentration and location of gadolinium and the cell ultrastructure
by: Julie Davies, et al.
Published: (2021-07-01)

Sample size calculation for clinical trials using cardiac magnetic resonance partition coefficient and extracellular volume fraction for the assessment of diffuse myocardial fibrosis
by: Liu Songtao, et al.
Published: (2013-01-01)

Late Gadolinium Enhancement in Cardiac Magnetic Resonance Imaging Is Associated with High Renal Resistive Index in Patients with Systemic Sclerosis
by: Rosario Cianci, et al.
Published: (2020-02-01)

Detection of late radiation damage on left atrial fibrosis using cardiac late gadolinium enhancement magnetic resonance imaging
by: Y. Jessica Huang, PhD, et al.
Published: (2016-04-01)

Myocardial late gadolinium enhancement cardiovascular magnetic resonance in patients with cirrhosis
by: Stremmel Wolfgang, et al.
Published: (2010-08-01)

The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T1 relaxometry in patients with prostate cancer
by: Nikita Sushentsev, et al.
Published: (2020-11-01)

Early detection of cardiac involvement in Miyoshi myopathy: 2D strain echocardiography and late gadolinium enhancement cardiovascular magnetic resonance
by: Kim Byoung, et al.
Published: (2010-05-01)